TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Benzinga Logo Benzinga By Prnewswire
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Dynavax Technologies has entered an exclusive worldwide license agreement with Vaxart to develop and commercialize an oral COVID-19 vaccine candidate, paying $25 million upfront and investing $5 million in equity, with potential future milestone payments.

Insights
IMXI   neutral

Being sold to The Western Union Company at $16.00 per share, representing a typical acquisition process


DVAX   positive

Company is expanding its vaccine portfolio with a potentially innovative oral COVID-19 vaccine platform, with limited financial risk and opportunity to evaluate Phase 2b data before full commitment